Oryzon Genomics S.A. (BME:ORY)

Spain flag Spain · Delayed Price · Currency is EUR
3.200
-0.050 (-1.54%)
Dec 5, 2025, 5:35 PM CET
109.42%
Market Cap 252.33M
Revenue (ttm) 7.36M
Net Income (ttm) -2.76M
Shares Out 78.85M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE 246.44
Dividend n/a
Ex-Dividend Date n/a
Volume 296,084
Average Volume 730,445
Open 3.275
Previous Close 3.250
Day's Range 3.190 - 3.275
52-Week Range 1.400 - 4.020
Beta 0.49
RSI 52.59
Earnings Date Feb 27, 2026

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 47
Stock Exchange Madrid Stock Exchange
Ticker Symbol ORY
Full Company Profile

Financial Performance

In 2024, Oryzon Genomics's revenue was $7.62 million, a decrease of -51.43% compared to the previous year's $15.69 million. Losses were -$3.79 million, 2.39% more than in 2023.

Financial numbers in USD Financial Statements

News

ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025

Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant, and €1...

4 months ago - Benzinga

Oryzon Genomics S.A. GAAP EPS of -$0.03

7 months ago - Seeking Alpha

Oryzon Genomics S.A. GAAP EPS of -$0.02

10 months ago - Seeking Alpha

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting

Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A...

11 months ago - Benzinga